Trial Profile
A Phase IIa Study of Recombinant Human Interleukin-22 IgG2-Fc (F 652) in Combination With Systemic Corticosteroids for the Treatment of Newly Diagnosed Grade II-IV Lower Gastrointestinal Acute Graft-versus-Host Disease (aGVHD) in Hematopoietic Stem Cell Transplantation Recipients (HSCT)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Nov 2022
Price :
$35
*
At a glance
- Drugs F 652 (Primary) ; Prednisone
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Evive Biotech
- 18 Nov 2022 Results published in the Blood
- 01 Jul 2021 Status changed from active, no longer recruiting to completed.
- 31 May 2019 Planned End Date changed from 1 Dec 2019 to 8 Mar 2020.